-
1
GLP-1 medications have become more affordable in the U.S., dropping to below $350 monthly due to federal pricing policy changes and direct-to-consumer platforms.
-
2
Despite increased access, early data show high discontinuation rates for GLP-1 therapy, indicating affordability alone may not ensure long-term treatment adherence.
-
3
Digital platforms like NovoCare and LillyDirect have facilitated direct access to GLP-1s, bypassing traditional insurance and pharmacy benefit managers.
-
4
The TrumpRx.gov platform connects cash-paying patients to reduced prices for GLP-1s, but purchases do not count towards insurance deductibles.
-
5
The success of the GLP-1 access model may not easily translate to other chronic conditions, as it relies on unique market dynamics and patient motivations.
